Notícias de CSPC Pharmaceutical Group

Últimas notícias

Manchetes no idioma original da fonte.

• 
  Big Pharma Is Pouring Billions Into China’s Biotechs (abre em uma nova aba)

  Barrons.com · 14 de set. de 2026

• 
  The Evolving EGFR NSCLC Market: 8 Emerging Late-stage Therapies to Watch | DelveInsight (abre em uma nova aba)

  PR Newswire · 1 de jun. de 2026

• 
  CSPC’s SYS6051 Trial Approval Adds New Angle To Valuation Story (abre em uma nova aba)

  Simply Wall St. · 22 de abr. de 2026

• 
  2026 ASCO Preview | Results from Phase III Study of Anbenitamab (KN026) Combined with HB1801 in Neoadjuvant Treatment for Breast Cancer Selected for LBA Oral Presentation (abre em uma nova aba)

  PR Newswire · 22 de abr. de 2026

• 
  Alphamab Oncology Announces the Phase III Clinical Study of Anbenitamab (KN026) Combined with HB1801 as Neoadjuvant Treatment for Breast Cancer Has Met the Primary Endpoint (abre em uma nova aba)

  PR Newswire · 1 de abr. de 2026

• 
  How Regulatory Approval for CSPC Pharmaceutical’s First C5 siRNA Therapy (SEHK:1093) Has Changed Its Investment Story (abre em uma nova aba)

  Simply Wall St. · 7 de nov. de 2025

• 
  Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates (abre em uma nova aba)

  GlobeNewswire · 4 de nov. de 2025

• 
  How Dual U.S. and China Trial Approvals for SYH2070 Could Shape CSPC (SEHK:1093) Investors' Outlook (abre em uma nova aba)

  Simply Wall St. · 13 de out. de 2025